Trials / Not Yet Recruiting
Not Yet RecruitingNCT07201714
Oral Carnitine in Heart Failure Patients
Oral L-Carnitine Supplementation in Cardiorenal Heart Failure Patients
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms like being more tired, shortness of breath, and swelling in the body. Carnitine is a naturally occurring substance in the body that plays a role in turning fat into energy. This study will determine whether oral L-Carnitine supplementation can improve symptoms, enhance heart function and possibly improve the quality of life in individuals with heart failure.
Detailed description
Heart failure (HF) is a multi-organ syndrome that is fundamentally driven by metabolic failure. Metabolic alterations include reduced fatty acid oxidation, which is the main fuel source for cardiac myocyctes in normal circumstances. Carnitine is a vitamin-like modified amino acid that is essential in the oxidation of fatty acids and has been found to be reduced in the heart failure population. Abnormalities in carnitine metabolism are thought to contribute to myocardial dysfunction, oxidative stress and inflammation. Carnitine supplementation may increase fatty acid oxidation, and therefore energy metabolism in heart failure patients, thus improving functional capacity, clinical measures and quality of life in this vulnerable patient population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levocarnitine | Oral L-carnitine, 2970mg daily (950mg, to be taken 3 times a day) for 3 months. |
Timeline
- Start date
- 2025-12-01
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2025-10-01
- Last updated
- 2025-10-01
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT07201714. Inclusion in this directory is not an endorsement.